MedTrace Logo

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study

NCT01823159 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-12-02

No results posted yet for this study

Summary

The objective of this study is to characterize the effects of a single-dose of retigabine on cortical excitability in healthy subjects, as quantified by means of TMS.

Conditions

Interventions

DRUG

retigabine

Single oral administration of a 400 mg tablet.

DRUG

placebo

Single oral administration of a tablet

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Université Catholique de Louvain

    collaborator OTHER

  • University Hospital of Mont-Godinne

    lead OTHER

Principal Investigators

  • Michel Ossemann, MD · CHU Mont-Godinne

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01823159 on ClinicalTrials.gov